NCM
VNDA icon

Nantahala Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Nantahala Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,593,516
Closed -$7.47M – 148
2024
Q3 		$7.47M Hold
1,593,516
– – 0.38% 56
2024
Q2 		$9M Buy
1,593,516
+580,265
+57% +$3M 0.53% 40
2024
Q1 		$4.16M Hold
1,013,251
– – 0.24% 71
2023
Q4 		$4.28M Buy
1,013,251
+13,251
+1% +$53.5K 0.26% 68
2023
Q3 		$4.32M Buy
+1,000,000
New +$5.56M 0.37% 60

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Nantahala Capital Management's VNDA Position: Q4 2024 in Review

Nantahala Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 1,593,516 shares — an estimated $7.47M sold.

Nantahala Capital Management first reported a position in VNDA in Q3 2023 and held it in 5 quarters. The position peaked at $9M in Q2 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

  • Nantahala Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 1,593,516 Vanda Pharmaceuticals shares in Q4 2024, an estimated $7.47M.
  • Nantahala Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Nantahala Capital Management's Vanda Pharmaceuticals position peaked at $9M in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.